Home Featured Page 273

Featured

Latest

Prophecy, Psychedelics, and Power in Dune

Psychedelic Drug Development Under Trump 2.0: Health Nominees Signal Uncertain Future

Is Cannabis a Psychedelic? Exploring the Science of Indoles, Interprening, and Intention

Q3’24 Survey: What are Psychedelics Investors Concerned About?

Interviews: Meet the Team Who Challenged the DEA on DOI and DOC

Interview With Yaron Conforti, Novamind

5-MeO-DMT: Can ‘Toad Juice’ Cure Depression?

The World’s First Psychedelic ETF Just Launched: Here’s Why That Matters

How Red Light Holland Is Bringing Psilocybin Truffles Mainstream

Why Ayahuasca Is Miley Cyrus’ ‘Favorite’ Drug

Patent Combining Psychedelics with Cannabinoids Allowed by USPTO

Mind Cure Announces Closing of $23 Million Bought Deal Offering Including...

Bright Minds Biosciences Strengthens Scientific Advisory Team to Prepare for Future...

Silo Pharma Announces Private Placement of Equity Definitive Agreement for $4.275...

1...272273274...276 Page 273 of 276

Prophecy, Psychedelics, and Power in Dune

Psychedelic Drug Development Under Trump 2.0: Health Nominees Signal Uncertain Future

Is Cannabis a Psychedelic? Exploring the Science of Indoles, Interprening, and...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Prophecy, Psychedelics, and Power in Dune

Psychedelic Drug Development Under Trump 2.0: Health Nominees Signal Uncertain Future

Is Cannabis a Psychedelic? Exploring the Science of Indoles, Interprening, and Intention

Q3’24 Survey: What are Psychedelics Investors Concerned About?

Interviews: Meet the Team Who Challenged the DEA on DOI and DOC

Interview With Yaron Conforti, Novamind

5-MeO-DMT: Can ‘Toad Juice’ Cure Depression?

The World’s First Psychedelic ETF Just Launched: Here’s Why That Matters

How Red Light Holland Is Bringing Psilocybin Truffles Mainstream

Interview With Carlos Tanner

Why Ayahuasca Is Miley Cyrus’ ‘Favorite’ Drug

Patent Combining Psychedelics with Cannabinoids Allowed by USPTO

Mind Cure Announces Closing of $23 Million Bought Deal Offering Including...

Bright Minds Biosciences Strengthens Scientific Advisory Team to Prepare for Future...

Silo Pharma Announces Private Placement of Equity Definitive Agreement for $4.275...

EDITOR PICKS

Prophecy, Psychedelics, and Power in Dune

Psychedelic Drug Development Under Trump 2.0: Health Nominees Signal Uncertain Future

Is Cannabis a Psychedelic? Exploring the Science of Indoles, Interprening, and...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY